Acumen Pharmaceuticals/ABOS

6.03%
-
1D1W1MYTD1YMAX

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimer’s pathology). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company is developing sabirnetug for intravenous (IV), administration every four weeks for the treatment of early AD.

Ticker

ABOS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Daniel O'Connell

Employees

51

Headquarters

Charlottesville, United States

ABOS Metrics

BasicAdvanced
US$219M
Market cap
-
P/E ratio
-US$1.05
EPS
-
Beta
-
Dividend rate
US$219M
US$11.31
US$1.81
306K
30.197
11.529
11.529
-22.89%
-25.36%
-23.72%
0.837
0.837
4.53%

What the Analysts think about ABOS

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
230.75% upside
High US$15.00
Low US$10.00
US$3.87
Current price
US$12.80
Average price target

ABOS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$0
NaN%
Net income
-US$15M
-9.76%
Profit margin
0%
NaN%

ABOS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.85%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-US$0.28
-US$0.24
-US$0.28
-US$0.25
-
Expected
-US$0.35
-US$0.27
-US$0.26
-US$0.26
-US$0.26
Surprise
-19.08%
-9.77%
7.69%
-3.85%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Acumen Pharmaceuticals stock?

Acumen Pharmaceuticals (ABOS) has a market cap of $219M as of May 20, 2024.

What is the P/E ratio for Acumen Pharmaceuticals stock?

The price to earnings (P/E) ratio for Acumen Pharmaceuticals (ABOS) stock is 0 as of May 20, 2024.

Does Acumen Pharmaceuticals stock pay dividends?

No, Acumen Pharmaceuticals (ABOS) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Acumen Pharmaceuticals dividend payment date?

Acumen Pharmaceuticals (ABOS) stock does not pay dividends to its shareholders.

What is the beta indicator for Acumen Pharmaceuticals?

Acumen Pharmaceuticals (ABOS) does not currently have a Beta indicator.

What is the Acumen Pharmaceuticals stock price target?

The target price for Acumen Pharmaceuticals (ABOS) stock is $12.8, which is 233.33% above the current price of $3.84. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Acumen Pharmaceuticals stock

Buy or sell Acumen Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing